Experientia

, Volume 35, Issue 6, pp 744–746 | Cite as

Absence of dopamine sensitive adenylate cyclase in the A10 region, the origin of mesolimbic dopamine neurones

  • H. P. Lorez
  • W. P. Burkard
Article

Summary

Dopamine (DA) failed to stimulate the adenylate cyclase of the mesolimbic A10 DA nerve cell body area, in contrast to its activating effect in the nigrostriatal A9 DA cell body area. The enzyme was stimulated by GMPPNP (a GTP analog) and NaF. This indicates the absence in the A10 cell area of DA receptors with functional coupling on adenylate cyclase, in contrast to the A9 cell area where such DA receptors are believed to be located on afferent axon terminals.

Keywords

Dopamine Nerve Cell Adenylate Cyclase Activate Effect Cell Area 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 2.
    U. Ungerstedt, Acta physiol. scand., suppl.367, 1 (1971).Google Scholar
  2. 3.
    J. W. Kebabian and J. M. Saavedra, Science193, 683 (1976).PubMedGoogle Scholar
  3. 4.
    O. T. Phillipson and A. S. Horn, Nature261, 418 (1976).PubMedGoogle Scholar
  4. 5.
    Y. C. Clement-Cormier, J. W. Kebabian, G. L. Petzold and P. Greengard, Proc. natl Acad. Sci. USA71, 1113 (1974).PubMedGoogle Scholar
  5. 6.
    J. W. Kebabian, Life Sci.23, 479 (1978).PubMedGoogle Scholar
  6. 7.
    K. Gale, A. Guidotti and E. Costa, Science195, 503 (1977).PubMedGoogle Scholar
  7. 8.
    O. T. Phillipson, P. C. Emson, A. S. Horn and T. Jessell, Brain Res.136, 45 (1977).PubMedGoogle Scholar
  8. 9.
    P. F. Spano, M. Trabucchi and G. Di Chiara, Science196, 1343 (1977).PubMedGoogle Scholar
  9. 10.
    A. Björklund and O. Lindvall, Brain Res.83, 531 (1975).PubMedGoogle Scholar
  10. 11.
    L. B. Geffen, T. M. Jessell, A. C. Cuello and L. L. Iversen, Nature260, 258 (1976).PubMedGoogle Scholar
  11. 12.
    M. J. Brownstein, E. A. Mroz, M. L. Tappaz and S. E. Leeman, Brain Res.135, 315 (1977).PubMedGoogle Scholar
  12. 13.
    M. C. Olianas, G. M. De Montis, G. Mulas and A. Tagliamonte, Eur. J. Pharmac.49, 233 (1978).Google Scholar
  13. 14.
    W. J. H. Nauta, G. P. Smith, R. L. M. Faull and V. B. Domesick, Neuroscience3, 385 (1978).PubMedGoogle Scholar
  14. 15.
    J. L. Waddington and A. J. Cross, Life Sci.22, 1011 (1978).PubMedGoogle Scholar
  15. 16.
    P. Wolf, H.-R. Olpe, D. Avrith and H. L. Haas, Experientia34, 73 (1978).PubMedGoogle Scholar
  16. 17.
    M. Palkovits, Brain Res.59, 449 (1973).PubMedGoogle Scholar
  17. 18.
    M. Palkovits and D. M. Jacobowitz, J. comp. Neurol.157, 29 (1974).PubMedGoogle Scholar
  18. 19.
    O. H. Lowry, N. J. Rosebrough, A. L. Farr and R. J. Randall, J. biol. Chem.193, 265 (1951).PubMedGoogle Scholar
  19. 20.
    Y. Salomon, M. C. Lin, C. Londos, M. Rendell and M. Rodbell, J. Biol. Chem.250, 4239 (1975).PubMedGoogle Scholar
  20. 21.
    B. L. Brown, J. D. M. Albano, R. P. Ekins and A. M. Sgherzi, Biochem. J.121, 561 (1971).PubMedGoogle Scholar
  21. 22.
    N. Sahyoun, C. J. Schmitges, H. Le Vine and P. Cuatrecasas, Life Sci.21, 1857 (1977).PubMedGoogle Scholar
  22. 23.
    L. S. Bradham, J. cyclic Nucleot. Res.3, 119 (1977).Google Scholar
  23. 24.
    W. P. Burkard, Experientia33, 788 (1977).Google Scholar
  24. 25.
    G. K. Aghajanian and B. S. Bunney, in: Frontiers in catecholamine research, p. 643. Ed. E. Usdin and S. H. Snyder, Pergamon, New York 1973.Google Scholar

Copyright information

© Birkhäuser Verlag 1979

Authors and Affiliations

  • H. P. Lorez
    • 1
  • W. P. Burkard
    • 1
  1. 1.Department of Pharmaceutical ResearchF. Hoffmann-La Roche & Co. LtdBaselSwitzerland

Personalised recommendations